Drugs

Article	Citations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	417
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	395
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	296
Bimekizumab for the Treatment of Psoriasis	282
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	218
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	190
Targeting DNA Damage Response Deficiency in Thoracic Cancers	169
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	161
Teclistamab: First Approval	136
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	135
Spesolimab for the Treatment of Generalized Pustular Psoriasis	117
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	113
Aprocitentan: First Approval	107
Eftrenonacog Alfa: A Review in Haemophilia B	107
Vorasidenib: First Approval	105
New Therapies on the Horizon for Primary Biliary Cholangitis	103
Epcoritamab: First Approval	100
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	98
Finerenone: First Approval	96
Upacicalcet: First Approval	94
Lenacapavir: First Approval	93
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	92
Dasiglucagon: First Approval	92
Cosibelimab: First Approval	91
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	89

Drugs in Development to Manage Acute Pain	88
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	87
Dostarlimab: First Approval	86
Atogepant: First Approval	84
Androgenetic Alopecia: Therapy Update	84
Olipudase Alfa: First Approval	84
Repotrectinib: First Approval	83
Mosunetuzumab: First Approval	82
Danicopan: First Approval	82
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	78
Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia	78
Olverembatinib: First Approval	76
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	76
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	75
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	75
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	73
Cancer Pain Treatment Strategies in Patients with Cancer	72
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	72
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	70
Correction to: Prevention and Treatment of Monkeypox	69
Dorzagliatin: First Approval	69
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	69
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	69
Correction to: Tapinarof Cream 1%: First Approval	68
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	67
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	66
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	66
Pozelimab: First Approval	66
The Place of Cannabinoids in the Treatment of Gynecological Pain	66
Sunvozertinib: First Approval	66
Tovorafenib: First Approval	64
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	64
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	63
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	62
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	62
Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	62
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	61
Gepirone Extended-Release: First Approval	61
Birch Bark Extract: A Review in Epidermolysis Bullosa	60
Correction to: Concizumab: First Approval	60
Ponesimod: First Approval	60
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	59
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	59
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	58
Asciminib: First Approval	57
Aumolertinib: A Review in Non-Small Cell Lung Cancer	57
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	57
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	56
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	55
Givinostat: First Approval	54

Ozoralizumab: First Approval	53
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	53
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	53
Tirzepatide: A Review in Type 2 Diabetes	52
Correction to: Remdesivir: A Review in COVID-19	51
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	50
Catumaxomab: First Approval	49
Disitamab Vedotin: First Approval	49
Correction to: Sotorasib: First Approval	49
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	49
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	49
Correction: Teprotumumab: A Review in Thyroid Eye Disease	48
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	48
Ensitrelvir Fumaric Acid: First Approval	48
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	47
Avacincaptad Pegol: First Approval	47
Fezolinetant: First Approval	47
Tisotumab Vedotin: First Approval	46
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	46
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	46
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	45
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	45
Futibatinib: First Approval	45
Zastaprazan: First Approval	45
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	44
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	43
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations	43
Eye Involvement and Management in Inherited Epidermolysis Bullosa	43
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	43
Correction: Iptacopan: First Approval	42
Gastrointestinal Dysfunction in Parkinson’s Disease	41
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	41
Lotilaner Ophthalmic Solution 0.25%: First Approval	41
Beremagene Geperpavec: First Approval	41
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	40
Savolitinib: First Approval	40
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	40
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	40
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	39
Imeglimin Hydrochloride: First Approval	39
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	39
Imetelstat: First Approval	39
Tebentafusp: First Approval	39
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	38
Acknowledgement to Referees	38
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	37
Retifanlimab: First Approval	36
Revumenib: First Approval	36
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	36
Nogapendekin alfa Inbakicept: First Approval	36
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	36
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	35
Crinecerfont: First Approval	34
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	34
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	34
Avatrombopag: A Review in Thrombocytopenia	33
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	33
Mavorixafor: First Approval	33
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	33
Diagnosis and Treatment of AL Amyloidosis	33
Correction to: Sparsentan: First Approval	32
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	32
Donafenib: First Approval	32
Antibacterials with Novel Chemical Scaffolds in Clinical Development	31
Correction to: Abrocitinib: First Approval	31
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	30
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	30
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	30
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	30
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis	30
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	29
Correction: Zastaprazan: First Approval	29
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care	29
Zolbetuximab: First Approval	29
Correction to: Spesolimab: First Approval	29
Methadone for Cancer Pain Management in Children: A Review of Literature	29
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?	28
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	28
Keverprazan Hydrochloride: First Approval	28
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	28

Remdesivir: A Review in COVID-19	27
Daridorexant: First Approval	27
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	27
Ravulizumab: A Review in Generalised Myasthenia Gravis	27
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	27
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	27
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	26
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	26
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	26
Spesolimab: First Approval	26
Odevixibat: First Approval	26
Abrocitinib: First Approval	26
Elranatamab: First Approval	25
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies	25
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	25
Marstacimab: First Approval	25
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	25
Regdanvimab: First Approval	25
Nadofaragene Firadenovec: First Approval	25
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	25
Gefapixant: First Approval	25
Pucotenlimab: First Approval	24
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	24
Amubarvimab/Romlusevimab: First Approval	24
Lecanemab: First Approval	24
Correction to: Rozanolixizumab: First Approval	24
Tixagevimab + Cilgavimab: First Approval	24
Molnupiravir: First Approval	24
Comment on: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	24
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions	24
Correction to: Contezolid: First Approval	23
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	23
Ritlecitinib: First Approval	23
Tofersen: First Approval	23
Correction to: Mavacamten: First Approval	23
Chiglitazar: First Approval	23
Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’	22
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer	22
New Developments in Glucagon Treatment for Hypoglycemia	22
Furmonertinib: First Approval	22
Acknowledgement to Referees	22
Comment on “Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review”	22
Talquetamab: First Approval	22
Correction to: Ozanimod: A Review in Ulcerative Colitis	21
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders	21
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study	21
Lazertinib: First Approval	20
Dimdazenil: First Approval	20
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis	20
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline	20
Elafibranor: First Approval	20
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	20
Valoctocogene Roxaparvovec: First Approval	20
Eplontersen: First Approval	20
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	20
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort St	19
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?	19
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	19
PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis	19
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease	19
Vamorolone: First Approval	19
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	19
Motixafortide: First Approval	18
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	18
Sotorasib: First Approval	18
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	18
Vosoritide: First Approval	18
Tirzepatide: First Approval	18
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	17
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	17
Sulbactam/Durlobactam: First Approval	17
Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC	17
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma	17
Linzagolix: First Approval	17
Tunlametinib: First Approval	17
Mirvetuximab Soravtansine: First Approval	17
Iptacopan: First Approval	17
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy	17
Authors’ Reply to Colak et al.: “Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing”	17
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	17
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	17
Drug-Induced Pigmentation: A Review	16
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	16
Tegileridine: First Approval	16
Results from Expanded Access Programs: A Review of Academic Literature	16
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	16
Nemolizumab: First Approval	16
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	16
Drugs in Development to Treat IgA Nephropathy	16
Evinacumab: First Approval	16
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	16
Correction to: Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	15
Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?	15
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review	15
A Multicentric, Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients	15